EMEA-002964-PIP01-21-M02

Table of contents

Key facts

Invented name
Ronapreve
Active substance
Casirivimab
Therapeutic area
Infectious diseases
Decision number
P/0300/2022
PIP number
EMEA-002964-PIP01-21-M02
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
  • Prevention of Coronavirus disease 2019 (COVID-19)
  • Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Roche Registration GmbH

E-mail: global.paediatrics@roche.com
Tel. +41 61 687 9411
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating